← All trials
NCT01002040
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 1, 2010
- Primary completion
- Jul 1, 2010
- Completion date
- Aug 1, 2010
- First posted
- —
- Last posted
- —
- Enrollment
- 150
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- University of British ColumbiaLead sponsor
- University of British ColumbiaOverall official - principal investigator
- McGill UniversityStudy director
- University of TorontoStudy director
- Dalhousie UniversityStudy director
- University of OttawaStudy director
- GlaxoSmithKlineCollaborator
- Canadian Institutes of Health Research (CIHR)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.